Ocular FIP treatment enters a more practical antiviral era

CURRENT BRIEF VERSION: Ocular feline infectious peritonitis, once a near-certain blinding or fatal diagnosis, is increasingly being managed with antiviral therapy, and the latest discussion in a VETgirl podcast highlights how treatment thinking is shifting for these cases. Drawing on a 2025 Royal Veterinary College case series, the podcast emphasizes that ocular FIP can present with vision changes, uveitis, iris color change, dyschoria, hyphema, hypopyon, fibrin, retinal lesions, hemorrhage, vascular tortuosity, detachment, or perivascular cuffing, sometimes as the first clue to systemic disease. The broader evidence base behind that shift centers on GS-441524 and remdesivir, which have shown high survival rates in treated cats, while clinicians have also recognized that ocular and neurologic cases often need higher dosing and closer monitoring because of blood-eye and blood-brain barrier penetration challenges. In the U.S., access changed materially in 2024 when FDA said it did not intend to enforce approval requirements for compounded GS-441524 prescribed by veterinarians for specific FIP patients under Guidance for Industry #256, and Cornell subsequently noted compounded oral GS-441524 became available through pharmacy channels on June 1, 2024. (fda.gov)

Why it matters: For veterinary professionals, ocular FIP is no longer just a diagnostic dead end. The practical question is now case selection, dosing, monitoring, and client counseling. Recent literature suggests antiviral therapy can reverse ocular disease in many cats, but it also underscores that ocular presentations may not fit simplified protocols developed for uncomplicated effusive disease, especially as shorter-course treatment studies have generally excluded cats with only ocular or neurologic signs. VETgirl’s related discussion of dosing and duration also reinforces that early clinical improvement within the first week does not necessarily mean viral clearance, and that treatment decisions may increasingly rely on objective trends such as serum amyloid A, alpha-1 acid glycoprotein, and the albumin:globulin ratio rather than appearance alone. That means veterinarians should be careful about extrapolating abbreviated regimens to these patients and should set expectations around follow-up exams, bloodwork, and the possibility of dose adjustment if ocular lesions persist. (pubmed.ncbi.nlm.nih.gov)

What to watch: Expect more discussion around standardized ocular and neurologic FIP dosing, treatment duration, biomarker-guided stopping rules, and practical diagnostic cues as newer retrospective studies, podcasts, and practice guidelines continue to emerge. VETgirl’s broader FIP update also notes that antivirals have pushed reported response rates into the roughly 85% to 90% range and sharpened attention on real-world diagnosis and follow-up. (pubmed.ncbi.nlm.nih.gov)